Metabolism - Clinical and Experimental
Volume 44, Issue 12 , Pages 1559-1563 , December 1995

Effect of l-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a)

Received 18 November 1994 ,Accepted 16 May 1995.

References 

  1. Lithell H, Boberg J, Hellsing K, et al.  Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase activity in overt and subclinical hypothyroidism: The effect of substitution therapy. Eur J Clin Invest. 1981;11:3–10
  2. Staub J-J, Althaus BU, Engler H, et al.  Spectrum of subclinical and overt hypothyroidism: Effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med. 1992;92:631–642
  3. Mishkel MA, Crowther SM. Hypothyroidism: An important cause of reversible hypefiipidemia. Clin Chim Acta. 1977;74:139–144
  4. Muls E, Rosseneau M, Blanton V, et al.  Serum lipids and apoproteins A-I, A-II, and B in primary hypothyroidism before and during treatment. Eur J Clin Invest. 1984;14:12–15
  5. Scanu AM, Scandiani L. Lipoprotein(a): Structure, biology, and clinical relevance. Adv Intern Med. 1991;36:249–270
  6. Scanu AM, Fless GM. Lipoprotein(a): Heterogeneity and biological relevance. J Clin Invest. 1990;85:1709–1715
  7. Mims MP, Paubatz JW, Ghazzaly KK, et al.  Interaction of LDL and Lp(a) with human fibroblasts. Chem Phys Lipids. 1994;67/68:145–152
  8. Thompson GR, Soutar AK, Spengel FA, et al.  Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism. In: Proc Natl Acad Sci USA. 78:1981;p. 2591–2595
  9. Chait A, Bierman EL, Albers JJ. Regulatory role of triiodothyronine in the degradation of low density lipoprotein by cultured human skin fibroblasts. J Clin Endocrinol Metab. 1979;48:887–889
  10. Dory L, Roheim PS. Rat plasma lipoproteins and apolipoproteins in experimental hypothyroidism. J Lipid Res. 1981;22:287–296
  11. Klausen IC, Nielsen FE, Hegedus L, et al.  Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a). Metabolism. 1992;41:911–914
  12. De Bruin TWA, Van Barlingen H, Trip MV-L, et al.  Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab. 1993;76:121–126
  13. Spandrio S, Sleiman I, Scalvini T, et al.  Lipoprotein(a) in thyroid dysfunction before and after treatment. Horm Metab Res. 1993;25:586–589
  14. Engler E, Riesen WF. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem. 1993;39:2466–2469
  15. Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism: Effect of levothyroxine therapy. Arch Intern Med. 1990;150:2097–2100
  16. Nilsson G, Nordlander S, Levin K. Studies on subclinical hypothyroidism with special reference to the serum lipid pattern. Acta Med Scand. 1976;200:63–67
  17. Kutty KM, Bryant DG, Farid NR. Serum lipids in hypothyroidism—A re-evaluation. J Clin Endocrinol Metab. 1978;46:55–60
  18. Feely J, Iqgal SJ, Isles TE, et al.  Total cholesterol ratio in hyperthyroidism, hypothyroidism, and subclinical hypothyroidism. Horm Metab Res. 1980;12:560–561
  19. Raziel A, Rosenzweig B, Botvinic V, et al.  The influence of thyroid function on serum lipid profile. Atherosclerosis. 1982;41:321–326
  20. Parle JV, Franklyn JA, Cross KW, et al.  Circulating lipids and minor abnormalities of thyroid function. Clin Endocrinol (Oxf). 1992;37:411–414
  21. Althaus BU, Staub JJ, Ryff-De Leche A, et al.  LDL/HDL changes in subclinical hypothyroidism: Possible risk factors for coronary heart disease. Clin Endocrinol (Oxf). 1988;28:157–163
  22. Caron P, Calazel C, Parra HJ, et al.  Decreased HDL cholesterol in subclinical hypothyroidism: The effect of l-thyroxine therapy. Clin Endocrinol (Oxf). 1990;33:519–523
  23. Siedel J, Hagele E, Ziegenhorne J, et al.  Reagent for enzymatic determination of serum cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29:1075–1080
  24. Nagele U, Hagele E, Sauer G, et al.  Reagent for enzymatic determination of serum total triglyceride with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984;22:165–174
  25. Warnick GR, Benderson J, Abers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantification of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379–1388
  26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein in the plasma without the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  27. Gaubatz JW, Cushing GL, Morrisett JD. Quantification, isolation, and characterization of human lipoprotein[a]. Methods Enzymol. 1986;129:167–186
  28. Ballantyne FC, Epenetos AA, Caslake M, et al.  The composition of low-density lipoprotein and very-low-density lipoprotein subfractions in primary hypothyroidism and the effect of thyroid hormone replacement therapy. Clin Sci. 1979;57:83–88
  29. Schreiner PJ, Morrisett JD, Sharrett AR, et al.  Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb. 1993;13:826–833
  30. Dahlen GH. Lipoprotein(a) in relation to atherosclerotic diseases. Prog Clin Biol Res. 1988;255:27–36
  31. Hoefler G, Harnoncourt F, Paschke E, et al.  Lipoprotein Lp(a): A risk factor for myocardial infarction. Arteriosclerosis. 1988;8:398–401
  32. Durrington PN, Ishola M, Hunt L, et al.  Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988;1:1070–1073
  33. Dahlen GH, Guyton JR, Attar M, et al.  Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758–765
  34. Hoff HF, Beck GJ, Skibinski CI, et al.  Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988;77:1238–1244
  35. Dahlen G, Berg K, Gillnas T, et al.  Lp(a) lipoprotein/prebeta 1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin Genet. 1975;7:334–341
  36. Brown SA, Morrisett JD, Boerwinkle E, et al.  The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb. 1993;13:1558–1566
  37. Berg K, Dahlen G, Borresen A-L. Lp(a) phenotypes, other lipoprotein parameters and family history of heart disease in middle-aged males. Clin Genet. 1979;16:347–352
  38. Kostner GM, Avogaro P, Cozzolato G, et al.  Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51–61
  39. Rosengren A, Wilhelmsen L, Erikson E, et al.  Lipoprorein(a) and coronary heart disease: A prospective casecontrol study in a general population sample of middle aged men. Br Med J. 1990;301:1248–1251

PII: 0026-0495(95)90075-6

Metabolism - Clinical and Experimental
Volume 44, Issue 12 , Pages 1559-1563 , December 1995

Article Tools